CHẤT LƯỢNG CUỘC SỐNG VÀ CÁC YẾU TỐ LIÊN QUAN Ở NGƯỜI BỆNH UNG THƯ VÚ CHƯA MÃN KINH GIAI ĐOẠN II-III ĐIỀU TRỊ BẰNG ỨC CHẾ BUỒNG TRỨNG VÀ THUỐC NỘI TIẾT BỔ TRỢ BẬC II

Abstract

Background: Hormone receptor-positive breast cancer is the most common subgroup. Stage II-III patients often require multimodal treatment (surgery, chemotherapy, radiotherapy, OFS and long-term endocrine therapy). At this stage, patients often suffer from many cumulative side effects such as vasomotor disorders, musculoskeletal pain, decreased physiological function and psychological disorders, leading to a significant decline in QOL compared to stage I. Subject and method: 103 premenopausal breast cancer patients stage II-III treated at Hanoi Oncology Hospital, from April 2024 to December 2024. Results: The mean age was 42.2 ± 4.8 years. Invasive ductal carcinoma predominated (77.7%), with the mean Ki-67 index being 28.6 ± 19.6; ER and PR were positive in 99.1% and 86.0%, respectively. The mean duration of endocrine therapy (AI combined with ovarian suppression) was 16.2 ± 14.4 months, with 69.9% of the treatment group >6 months. The most commonly reported adverse effects were musculoskeletal pain (53.4%) and hot flashes (77.7%). The median total quality of life score according to FACT-ES was 64.0 (IQR 44.5–83.3). Two factors had a statistically significant association with FACT-ES score: Depression (PHQ-9 ≥10): β = 32 (95% CI: 12–53; p = 0.002); Sleep disturbance (ISI ≥8): β = 14 (95% CI: 1.7–26; p = 0.026) . Conclusions: Despite their important role, OFS and/or AIs are also associated with various adverse effects that can significantly impact the patient's quality of life if not properly managed and may lead to premature treatment discontinuation. Appropriate support strategies are needed to mitigate negative effects and improve the patient's treatment experience